Patients with HER2-positive breast cancer, a particularly aggressive form of breast cancer, now have a new, effective and less toxic therapeutic option. On Feb., 22, the U.S. Food and Drug Administration (FDA) approved the new treatment drug, Kadcyla (trastuzumab emtansine), also known as TDM-1, which combines Traztuzumab, also called Herceptin, with the powerful chemotherapy drug emtansine.
Fuente : http://feeds.sciencedaily.com/~r/sciencedaily/~3/z...
Fuente : http://feeds.sciencedaily.com/~r/sciencedaily/~3/z...